- Home
- XPEL vs TSHA Comparison
XPEL vs TSHA Comparison
Compare XPEL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | TSHA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | XPEL | TSHA |
|---|---|---|
| Price | $52.91 | $5.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 229.1K | ★ 3.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | $6,310,000.00 |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $30.83 | ★ N/A |
| Revenue Growth | ★ 10.29 | N/A |
| 52 Week Low | $24.25 | $1.05 |
| 52 Week High | $52.39 | $6.02 |
Technical Indicators
Market Signals| Indicator | XPEL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 78.08 | 60.48 |
| Support Level | $48.55 | $5.37 |
| Resistance Level | $51.29 | $6.02 |
| Average True Range (ATR) | 1.43 | 0.28 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 90.48 | 71.26 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.